Day 2 :
Seoul National University, Republic of Korea
Yu-Kyoung Oh has completed her bachelor and master degrees from Seoul National University, and Ph.D. degree from State Univ. of New York at Buffalo in 1994. She obtained postdoctoral training at Harvard Medical School (1994-1996). Her research interests focus on delivery of chemical drugs and nucleic acid-based drugs using versatile nanobiomaterials. She has published more than 180 papers in reputed journals and has been serving as an as an associate editor for Journal of Controlled Release, and Asian Journal of Pharmaceutical Sciences, and as an editorial board member of Advanced Drug Delivery Review, and Acta Pharmaceutica Sinica B.
Nanostructures such as nanosheets, and nanoballs have been studied for delivery of chemical anticancer drugs and oligonucleotides. Graphene-based nanosheets were studied for tumor microenvironment-responsive anticancer drug delivery. The biofunctionalization of graphene-based nanosheets with melittin peptide derivatives of phospholipids selectively activated the release of melittin in tumor microenvironment. The activation of pore-forming melittin in tumor tissues increased delivery of anticancer drug-loaded GNS to tumor cells. Moreover, the overexpression of matrix metalloproteinase (MMP) in tumor microenvironment was used for responsive delivery systems. We designed graphene oxide (GO) nanotheranostics loaded with MMP-activable image probe derivative and therapeutic peptide. As an MMP-activable therapeutic model molecule, pore-forming bufforin IIb chimeric peptide with GO-anchoring peptide at the end was designed. GO loaded with imaging probe derivative and bufforin chimeric peptide did not show fluorescence due to the quenching of the probe by GO. However, in the presence of MMP-2, the surface-modified GO selectively recovered fluorescence by liberating PEG-Cy5.5 conjugate moiety to environment and killing of tumor cells. Moreover, the surface-modified GO did not exert pore-forming activity in the absence of MMP. The MMP-sensitive de-shielding of PEG resulted in the exposure and sequential activation of therapeutic peptide on GO. In SCC7 tumor-bearing xenograft, the surface-modified GO showed the activated recovery of fluorescence at tumor tissues, and greater antitumor effect than other comparison groups. These studies provide the potential of tumor microenvironment-responsive delivery and imaging systems for next generation nanomedicine products.
Kingston University, London
Professor Raid Alany is a registered New Zealand Pharmacist with a PhD from the University of Otago, Dunedin, New Zealand. He is the Inaugural Head of School of Life Sciences, Pharmacy and Chemistry at Kingston University London, UK; holds an honorary professorship at the University of Auckland, New Zealand. He is the Editor-in-Chief of Pharmaceutical Development and Technology (Taylor and Francis) and Past President of the New Zealand Chapter of the Controlled Release Society. Raid’s research is on ophthalmic drug delivery, lipid and surfactant-based systems, in-situ gels and animal health. He holds international patents that have been commercialized in New Zealand and Australia where he consults for animal health companies, regulatory bodies and IP-specialized law firms. His ResearchGate score is 39.23 and his h-index is 23 (google scholar).
Currently, there are 26 UK-based universities that offer the Master of Pharmacy (MPharm) degree which is one of the main requirements to practice pharmacy in the UK. To registrar as a pharmacist in the UK, one must successfully complete a GPhC accredited (MPharm) course, which is a full-time, four-year course followed by successful completion of one year's pre-registration training, a period of paid employment in a community or hospital pharmacy during which a trainee is required to build up a portfolio of evidence and demonstrate their competence whilst being observed at work. This is followed by successful completion of the GPhC's registration exam along with meeting the fitness to practice requirements for registration as a pharmacist. On the other hand; courses in pharmaceutical sciences (BSc and MSc) throughout the UK are aimed at training graduates and preparing them to work in the pharmaceutical industry or specialize in regulatory affairs or clinical trials.
Universities in the UK are reaching out to universities around the world to establish partnerships for joint provision. Such partnerships could come in various shapes and forms. The QAA UK Quality Code defines collaborative provision as ‘learning opportunities leading or contributing to the award of academic credit or a qualification that are delivered, assessed or supported through an arrangement with one or more organisations other than the degree-awarding body’. Validation, franchise, dual degree, double degree, joint degree, articulation and placements are terms that are used in this context and could be rather confusing.
This key note will cover the key aspects of pharmacy / pharmaceutical sciences education in the UK. This will be followed by an explanation of the various forms of joint academic provision that are already in place and are available to pursue by universities in Europe should they wish to partner with a UK-based university.